NanoTag Biotechnologies GmbH develops single-domain antibodies and recombinant proteins for biomedical research and pre-clinical studies. Based in Göttingen, Germany, the company combines antibody discovery, protein production, and proprietary technologies to create affinity reagents designed for reliable, precise, and reproducible applications. Its product range includes FluoTags for enhanced immunofluorescence, Smart Secondaries for antibody detection and multiplexing, selector resins for affinity purification and pulldown experiments, and camelid single-domain antibodies for diverse research uses.

Specialized reagents support applications such as live-cell imaging, super-resolution microscopy, STED, confocal imaging, and detection of tagged proteins. NanoTag also offers customized contract research services, including tailored sdAb discovery, protein production, antibody modifications, and functional validation. Its discovery pipeline generates and characterizes antibodies against specific targets, including candidates with potential therapeutic applications.

The company’s stated goal is to provide high-quality recombinant affinity molecules for research and to support therapeutic and diagnostic industries. Through its products and custom services, NanoTag helps scientists address complex experimental and development challenges